PubMed Health⌕ Search

Biomedical subjects

S J Relf

Publications and source records attributed to S J Relf.

3 recordsLinked to original sources

Primary orbital intraosseous hemangioma.

Primary orbital intraosseous hemangiomas are rare--only 16 cases have been reported previously. The authors describe five patients with this benign tumor. Patients ranged in age from 49 to 77 years, and each had a painless or mildly tender nodular lesion. Ophthalmic symptoms were minimal, although nasolacrimal obstruction was the original sign in one patient. Four of five patients responded well to complete tumor excision (two patients) or partial resection of the lesion (two patients). The fifth patient required a second operation for tumor progression after partial excision of the hemangioma. The 16 previously reported cases of orbital intraosseous hemangioma are reviewed, and the natural history and pathology of this rare vascular lesion are discussed.

Aged↗

Thymoxamine reverses phenylephrine-induced mydriasis.

We performed a randomized double-masked evaluation of the alpha-adrenergic blocking agent thymoxamine (0.1%) as compared to placebo for the reversal of phenylephrine-induced mydriasis. Topically applied thymoxamine reversed the mydriasis from a single drop of 2.5% phenylephrine in 36 of 40 eyes (90%) within one hour. The mydriasis was completely reversed in 25 of 40 eyes (63%). Eyes with blue irides responded more quickly and more completely than did those with brown irides. The 40 contralateral eyes, which had also been dilated with phenylephrine, remained dilated or dilated further after receiving a placebo eyedrop. Twenty subjects (50%) reported mild transient ocular irritation upon instillation of thymoxamine. Thymoxamine was useful in individuals with narrow anterior chamber angles who were at risk of acute closed-angle glaucoma following dilation with an adrenergic agent.

Adult↗

Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145).

Apraclonidine hydrochloride (ALO 2145), a clonidine derivative that does not cross the blood-brain barrier, was applied topically to one eye of each of 20 normal human subjects. The rate of aqueous humor flow and the permeability of the blood-aqueous barrier were measured by fluorophotometry. Four hours after administration, the flow rate in the apraclonidine-treated eyes was 35% lower than that measured in the control eyes. Three hours after instillation, the intraocular pressure (IOP) was 34% lower in the apraclonidine-treated eyes when compared with control eyes. Both these differences were statistically significant. The drug had little, if any, effect on blood-aqueous permeability.

Administration, Topical↗